Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arrowhead Research Corporation and Merck have entered into an agreement to evaluate a proprietary therapeutic monoclonal antibody candidate evolved from Arrowhead's human-derived peptide targeting and discovery program.
Subscribe to our email newsletter
As part of the agreement, Merck will bear the costs involved in evaluating the candidate, which Arrowhead obtained from Alvos Therapeutics in April 2012.
Arrowhead president and CEO Chris Anzalone said Arrowhead is excited to work with Merck as it evaluates the antibody candidate.
"We believe that our human-derived library of targeting peptides and novel receptors is the world’s largest and can be used with many classes of drugs across multiple indications to enhance efficacy and decrease side effects," Anzalone added.
The discovery and delivery platform consists of a library of human-derived peptide sequences selected for the ability to bind cell surface targets and rapidly internalize within cells of more than 30 distinct tissues and multiple tumor types.
The discovery process involves screening human patients under strict ethical guidelines.